雄激素受体剪接变异体7与全长雄激素受体表达和临床结局相关:去势抵抗性前列腺癌患者的转化研究
研究前瞻性收集73例去势抵抗性前列腺癌患者首次或二线雄激素受体(AR)靶向治疗前的血浆,用微滴式数字PCR检测外泌体中AR-FL与AR-V7 mRNA。结果显示AR-FL在全部患者中可检出,22%患者基线AR-V7阳性,AR-V7阳性者AR-FL表达显著更高;AR-V7阴性者中位无进展生存期和总生存期均显著长于阳性者。
要点
- 73例去势抵抗性前列腺癌患者中,22%基线AR-V7阳性,AR-FL全部可检出。
- AR-V7阳性患者AR-FL表达显著高于AR-V7阴性患者(P < 0.0001)。
- 按AR-FL表达三分位分组,低、中、高三分位组中位无进展生存期分别为22、18、4个月(P = 0.0003)。
核心结论
- AR靶向治疗耐药与AR-V7存在相关,AR-FL表达可能有助于进一步细化患者对AR靶向治疗的反应和生存。
- 作者认为两种生物标志物若在前瞻性试验中得到验证,可用于选择最佳治疗策略。
研究设计与样本
- 前瞻性收集73例去势抵抗性前列腺癌患者首次或二线AR靶向治疗前的血浆样本。
- 从外泌体中分离mRNA,采用微滴式数字PCR分析AR-FL和AR-V7。
主要发现
- AR-FL在所有患者中均可检出,22%的患者基线AR-V7阳性。
- AR-V7阳性患者AR-FL表达显著高于AR-V7阴性患者(P < 0.0001)。
- 按AR-FL表达三分位分组,低三分位组、中三分位组、高三分位组的中位无进展生存期分别为22个月、18个月、4个月(P = 0.0003)。
- AR-V7阴性患者中位无进展生存期显著长于AR-V7阳性患者(20个月 vs 4个月,P < 0.0001)。
- AR-V7阴性患者中位总生存期显著长于AR-V7阳性患者(未达到 vs 9个月,P < 0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate if full-length androgen receptor (AR-FL) is associated with resistance to androgen receptor (AR)-directed therapy independently and/or combined with AR splice variant 7 (AR-V7). PATIENTS AND METHODS: Plasma samples were prospectively collected from 73 patients with castrate-resistant prostate cancer before first- or second-line AR-directed therapy. mRNA was isolated from exosomes and AR-FL and AR-V7 were analysed by droplet digital PCR. RESULTS: AR-FL was detected in all patients and 22% of them were AR-V7-positive at baseline. AR-FL expression was significantly higher in AR-V7-positive vs AR-V7-negative patients (P < 0.0001). After stratifying patients by tertile for AR-FL expression, progression-free survival (PFS) was 22 vs 18 vs 4 months for lower vs intermediate vs higher tertile, respectively (P = 0.0003). The median PFS and overall survival were significantly longer in AR-V7-negative vs AR-V7-positive patients (20 vs 4 months, P < 0.0001; not reached vs 9 months, P < 0.0001, respectively). CONCLUSIONS: Resistance to AR-directed therapy was associated with the presence of AR-V7; however, AR-FL expression may help better refine response and survival of patients to AR-directed therapy. Both biomarkers, if validated in prospective trials, could be used to select the best treatment strategy.
引用
- Del Re M, Crucitta S, Sbrana A, et al. Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer. BJU Int. 2019. PMID: 31055861. doi:10.1111/bju.14792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。